TY - JOUR T1 - Outcome of Nasal High Flow Nasal Oxygen Therapy (HFNO) in Acute Hypoxemic Respiratory Failure (AHRF) on an Acute Respiratory Care Unit (ARCU) JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.sleepandbreathing-2021.57 VL - 7 IS - suppl 7 SP - 57 AU - H Elfaki AU - E Jenkinson AU - E Baron AU - L Jacob AU - R Carney AU - M Yousif AU - A Dwarakanath Y1 - 2021/04/16 UR - http://openres.ersjournals.com/content/7/suppl_7/57.abstract N2 - Background: HFNO is considered as a treatment option in patients with de novo AHRF prior to intubation or where admission to ICU is deemed inappropriate.We retrospectively reviewed the clinical outcomes of all patients who received NHFO over 12 months in our ARCU.Method: Patients identified from the admission database were evaluated for length of stay(LOS),duration of HFNO,clinical outcome,in-hospital and 90-day mortality.A subgroup analysis between the survivors and non survivors was done to evaluate for any predictive parameters.Results: 71 patients [age-72 +/-13,males-68%] were included.90% (n=64) had significant co-morbidities (cardio-respiratory, metabolic and malignancy).Diagnosis on admission was Pneumonia(76%), Pulmonary Oedema(11%),Pulmonary Embolism(6%),ILD(6%) and Pneumothorax(1%).72% were not for escalation to level 3 care and had an active Do not resuscitate status.The median LOS on ARCU was 4 (2-8) days and median duration of HFNO was 3 (2-6) days.86% (n=61) had HFNO only,8%(n=6) were escalated to CPAP/NIV,3% (n=2) were transferred to ICU.The in hospital and 90 day mortality was 42% and 63%.Subgroup analysis between survivors and non survivors showed no significant difference in age(71 +/-12 v/s 73 +/-14,P=0.5),gender(P=0.61,OR=0.41),WHO PS(P=0.15,OR=0.95),RR(25 +/-6 v/s 26+/-5, P= 0.34) and PO2(7.8 +/-1.6 v/s 7.4 +/-1.4,OR=0.22).Conclusions: HFNO can be an option both in de novo AHRF and in patients who are deemed not for invasive ventilation.Patients with ILD subgroup have a high failure rates with worse mortality and early palliation may be beneficial.Further large scale studies are warranted to evaluate the role of NHFO in ILD.FootnotesCite this article as ERJ Open Research 2021; 7: Suppl. 7, 57.This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -